Preferred Label : Fingolimod;
NCIt definition : An orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1,
S1P1) modulator, with potential anti-inflammatory and immunomodulating activities.
Upon oral administration, fingolimod, as a structural analogue of sphingosine, selectively
targets and binds to S1PR1 on lymphocytes and causes transient receptor activation
followed by S1PR1 internalization and degradation. This results in the sequestration
of lymphocytes in lymph nodes. By preventing egress of lymphocytes. fingolimod reduces
both the amount of circulating peripheral lymphocytes and the infiltration of lymphocytes
into target tissues. This prevents a lymphocyte-mediated immune response and may reduce
inflammation. S1PR1, a G-protein coupled receptor, plays a key role in lymphocyte
migration from lymphoid tissues. Fingolimod also shifts macrophages to an anti-inflammatory
M2 phenotype, and modulates their proliferation, morphology, and cytokine release
via inhibition of the transient receptor potential cation channel, subfamily M, member
7 (TRPM7).;
UNII : 3QN8BYN5QF;
InChIKey : KKGQTZUTZRNORY-UHFFFAOYSA-N;
CAS number : 162359-55-9;
Chemical formula : C19H33NO2;
ChEBI ID : CHEBI:63115;
Origin ID : C74202;
UMLS CUI : C1699926;
Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- concept_is_in_subset
- has_salt_form
- has_target
- is_free_acid_or_base_form_of
